202 related articles for article (PubMed ID: 24512910)
1. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
Collura A; Lagrange A; Svrcek M; Marisa L; Buhard O; Guilloux A; Wanherdrick K; Dorard C; Taieb A; Saget A; Loh M; Soong R; Zeps N; Platell C; Mews A; Iacopetta B; De Thonel A; Seigneuric R; Marcion G; Chapusot C; Lepage C; Bouvier AM; Gaub MP; Milano G; Selves J; Senet P; Delarue P; Arzouk H; Lacoste C; Coquelle A; Bengrine-Lefèvre L; Tournigand C; Lefèvre JH; Parc Y; Biard DS; Fléjou JF; Garrido C; Duval A
Gastroenterology; 2014 Feb; 146(2):401-11.e1. PubMed ID: 24512910
[TBL] [Abstract][Full Text] [Related]
2. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Kim KJ; Rhee YY; Oh S; Cho NY; Lee HS; Kang GH
Mod Pathol; 2014 Mar; 27(3):443-53. PubMed ID: 24030751
[TBL] [Abstract][Full Text] [Related]
3. Deletion in HSP110 T
Kim KJ; Lee TH; Kim JH; Cho NY; Kim WH; Kang GH
Hum Pathol; 2017 Sep; 67():109-118. PubMed ID: 28811251
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
5. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.
Dorard C; de Thonel A; Collura A; Marisa L; Svrcek M; Lagrange A; Jego G; Wanherdrick K; Joly AL; Buhard O; Gobbo J; Penard-Lacronique V; Zouali H; Tubacher E; Kirzin S; Selves J; Milano G; Etienne-Grimaldi MC; Bengrine-Lefèvre L; Louvet C; Tournigand C; Lefèvre JH; Parc Y; Tiret E; Fléjou JF; Gaub MP; Garrido C; Duval A
Nat Med; 2011 Sep; 17(10):1283-9. PubMed ID: 21946539
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
Des Guetz G; Lecaille C; Mariani P; Bennamoun M; Uzzan B; Nicolas P; Boisseau A; Sastre X; Cucherousset J; Lagorce C; Schischmanoff PO; Morere JF
Anticancer Res; 2010 Oct; 30(10):4297-301. PubMed ID: 21036755
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability in the management of stage II colorectal patients.
Strâmbu V; Garofil D; Pop F; Radu P; Brătucu M; Iorga C; Iorga R; Pasnicu C; Ion A; Popa F
Chirurgia (Bucur); 2013; 108(6):816-21. PubMed ID: 24331320
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
9. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
10. Dominant high expression of wild-type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole-section immunohistochemical analysis.
Oh HJ; Kim JH; Lee TH; Park HE; Bae JM; Lee HS; Kang GH
APMIS; 2017 Dec; 125(12):1076-1083. PubMed ID: 28971530
[TBL] [Abstract][Full Text] [Related]
11. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
12. Role of microsatellite instability in the management of colorectal cancers.
Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
14. Major improvement in the detection of microsatellite instability in colorectal cancer using HSP110 T17 E-ice-COLD-PCR.
How-Kit A; Daunay A; Buhard O; Meiller C; Sahbatou M; Collura A; Duval A; Deleuze JF
Hum Mutat; 2018 Mar; 39(3):441-453. PubMed ID: 29227006
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO
Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
20. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
